To search for therapeutic targets in pancreatic cancer with SEMA6C downregulation, we applied L1000CDS2 analysis and found that cell cycle-related inhibitors, including those against topoisomerase or CDK4/6, may be potential drugs for the treatment of SEMA6C-low pancreatic tumors (Figure 5A). Here, CDK4 is linked to familial pancreatic carcinoma.